GO:0035639 purine ribonucleoside triphosphate binding

GO:0035639 purine ribonucleoside triphosphate binding is a molecular function term in the Gene Ontology that captures the ability of a protein or RNA molecule to selectively bind a purine ribonucleoside triphosphate, that is, a purine base linked to a ribose sugar esterified with a triphosphate group. The term covers binding of ATP, GTP, deoxy versions and related purine NTPs, and it is the functional prerequisite for phosphoryl transfer, nucleotide hydrolysis, helicase translocation and nucleotide-dependent conformational switching. Because purine NTPs are the principal energy currency and signalling nucleotides of the cell, this binding function is embedded in a very large fraction of the proteome, from RNA polymerases and kinases to small GTPases and ABC transporters. Historically, purine NTP binding was mapped biochemically using nucleotide analogues. Smith and colleagues used purine nucleoside 5'[gamma-S]triphosphates as affinity probes to analyse RNA initiated in isolated mouse myeloma nuclei, demonstrating direct and specific interaction of transcription machinery with purine NTP substrates. Freund and colleagues later identified a nucleoside triphosphate binding site on calf thymus RNA polymerase II, providing one of the earliest direct binding-site characterizations for this GO term. These studies established the experimental logic that still underpins the field: define the nucleotide, define the protein, then test binding and function. For modern researchers, GO:0035639 is a useful annotation axis because it groups proteins by a shared biochemical capability rather than by sequence family. Proteomic and bioinformatic studies of disease tissue repeatedly recover purine NTP-binding proteins among differentially expressed or functionally enriched modules, for example in ischemic stroke and vascular dementia, in host immune responses to Salmonella Enteritidis, and in bioprocess-related proteomic surveys. The term therefore connects mechanistic enzymology to disease biomarker discovery and to CRISPR-based functional validation.

In plain terms, GO:0035639 describes the act of a molecule grabbing and holding a purine ribonucleoside triphosphate. The QuickGO definition states that this is binding to a purine ribonucleoside triphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with triphosphate on the sugar. The synonym purine NTP binding is used interchangeably. The term is a molecular_function annotation: it says what the gene product does at the biochemical level, not where it acts or which pathway it belongs to. It is agnostic about whether binding leads to hydrolysis, phosphoryl transfer, allosteric regulation or simple sequestration, and it does not by itself specify affinity, stoichiometry or cofactor requirements. Experimentally, the function is demonstrated by direct binding assays, nucleotide analogue crosslinking, affinity chromatography or structural determination of a protein-nucleotide complex.

Purine ribonucleoside triphosphate binding is important because it is the molecular gateway to most energy-dependent and nucleotide-dependent processes in the cell. Without selective binding of ATP or GTP, kinases could not phosphorylate substrates, polymerases could not select the correct incoming nucleotide, helicases could not couple NTP hydrolysis to strand separation, and small GTPases could not act as molecular switches. Because the function is so widely distributed, changes in the binding properties of individual proteins can propagate into transcription, translation, metabolism, cytoskeletal dynamics and immune signalling. This breadth explains why purine NTP-binding proteins recur as biomarkers and candidate drug targets in proteomic and bioinformatic studies of stroke, vascular dementia and infection, and why purine NTP-binding enzymes such as AMP deaminase are studied as models for substrate recognition at metallocentres.

The following genes and protein families are representative carriers of purine ribonucleoside triphosphate binding activity and are frequently studied in mechanistic, biomarker and CRISPR functional-genomics research.

Purine ribonucleoside triphosphate binding is regulated at several levels. Intracellular ATP and GTP concentrations set the substrate availability for all binding reactions, so purine biosynthesis, salvage and energy metabolism indirectly control occupancy. Post-translational modifications such as phosphorylation can alter the conformation of nucleotide-binding pockets and change affinity. Allosteric ligands and partner proteins further tune binding, as seen in the nucleotide-dependent switching of GTPases and in the metal-dependent substrate positioning of AMP deaminase. At the expression level, transcriptomic and proteomic studies show that purine NTP-binding proteins are differentially abundant in disease states such as ischemic stroke and vascular dementia, indicating that regulation also occurs through changes in protein synthesis and degradation. In infection settings, immune-cell transcriptional programmes reshape the abundance of nucleotide-binding proteins, linking host regulation to pathogen challenge.

Bioinformatic identification of biomarkers and therapeutic targets for ischemic stroke and vascular dementia has highlighted purine nucleotide-binding proteins among differentially expressed and functionally enriched gene sets. Because these proteins participate in energy metabolism, nucleotide signalling and transcriptional control, their dysregulation may contribute to neuronal vulnerability and vascular cognitive impairment. The same study framework supports using purine NTP-binding candidates as biomarkers and as starting points for targeted intervention.

AMP deaminase, a purine nucleotide-binding enzyme with a dinuclear zinc metallocentre, is a model for substrate recognition in purine metabolism. Altered AMP deaminase activity affects the purine nucleotide pool and has been linked to exercise intolerance and metabolic phenotypes. Structural and biochemical characterisation of its substrate interactions provides a rationale for interpreting disease-associated variants that perturb nucleotide binding.

Proteomic analysis of naive and vaccinated chickens during Salmonella Enteritidis infection revealed distinct roles for CD4, CD8 and gamma-delta T lymphocytes and identified nucleotide-binding proteins among the immune-response proteome. This illustrates how purine NTP-binding functions are embedded in host defence and how vaccination reshapes their abundance. Such findings support the use of purine NTP-binding proteins as markers of immune activation.

Because purine NTP binding is required for DNA replication, transcription and kinase signalling, proteins carrying this function are frequently overexpressed in proliferating cells. Proteomic surveys in other biological systems have shown that nucleotide-binding proteins are abundant and functionally enriched, providing methodological templates for cancer proteomics. Targeting nucleotide-binding pockets is therefore a long-standing strategy in anticancer drug discovery, although the therapeutic window depends on the specific protein family.

Purine nucleoside 5'[gamma-S]triphosphates and related analogues can be used as affinity probes to capture proteins engaged with purine NTP substrates. Smith and colleagues used this approach to analyse RNA initiated in isolated mouse myeloma nuclei, demonstrating direct labelling of transcription complexes. The method remains useful for identifying nucleotide-binding proteins in complex lysates and for confirming that a candidate protein directly contacts the nucleotide.

Isothermal titration calorimetry, surface plasmon resonance and fluorescence polarisation can quantify affinity for ATP or GTP. Structural methods such as X-ray crystallography and cryo-EM define the binding pocket and metal coordination. The identification of a nucleoside triphosphate binding site on calf thymus RNA polymerase II is an early example of combining biochemical mapping with mechanistic interpretation, while characterisation of the AMP deaminase metallocentre shows how metal coordination can be resolved in detail.

Mass spectrometry-based proteomics can quantify purine NTP-binding proteins across conditions. Proteomic investigation of IgY purification and product development illustrates how nucleotide-binding proteins appear among enriched functional categories in applied workflows. In disease research, bioinformatic enrichment of purine NTP-binding annotations helps prioritise biomarkers and therapeutic targets, as shown for ischemic stroke and vascular dementia and for immune responses to Salmonella Enteritidis.

RNA-seq, Ribo-seq and phosphoproteomics can be combined with CRISPR perturbation to test whether purine NTP-binding activity is required for transcriptional, translational or signalling outputs. Knockout of a nucleotide-binding protein followed by pathway enrichment analysis provides a direct link between the molecular function and the cellular phenotype, and is a standard approach in modern functional genomics.

Researchers studying purine ribonucleoside triphosphate binding-related genes often need to determine whether a candidate gene is causally involved in a disease or pathway, rather than merely correlated with it. The most rigorous way to establish causality is to perturb the gene precisely and measure the consequence. This requires knockout, point-mutation, knock-in and overexpression models that are isogenic, validated and reproducible, together with screening and bioinformatics support to interpret the resulting data.

GO:0035639 purine ribonucleoside triphosphate binding defines a fundamental molecular capability that underlies energy transfer, nucleic acid synthesis, mechanical work and signal transduction. Its experimental history, from nucleotide analogue affinity probes to RNA polymerase II binding-site mapping and metallocentre characterisation, provides a robust framework for modern research. Because purine NTP-binding proteins are enriched in disease biomarker signatures and are tractable to precise genetic perturbation, they remain high-value targets for mechanistic and translational studies. Combining CRISPR knockout, point-mutation, knock-in and overexpression models with proteomic, transcriptomic and bioinformatic readouts allows researchers to move from annotation to causality. This integrated approach is well suited to identifying which purine NTP-binding proteins drive specific diseases and to prioritising them for therapeutic development.